Article citationsMore>>

F. K. Li, L. Y.Chan , J. C. Woo, et al., “A 3-Year, Prospective, Randomized, Controlled, Study on Amino Acid Dialysate in Patients on CAPD,” American Journal of Kidney Diseases, Vol. 42, No. 1, 2003, pp. 173-183. doi:10.1016/S0272-6386(03)00421-9

has been cited by the following article:

• TITLE: Do We Have a Biocompatible Peritoneal Dialysis Fluid?

  AUTHORS: Shadi Hassan, Batya Kristal, Khalid Khazim, Fadi Hassan, Dunia Hassan, Kamal Hassan

  KEYWORDS: Icodextrin; Amino Acids PDF; Homocyteine; Carbohydrates; Lipids; Inflammation

  JOURNAL NAME: Open Journal of Nephrology, Vol.2 No.3, September 26, 2012

  ABSTRACT: Objective: Cardiovascular disease remains the leading cause of morbidity and mortality in patients on maintenance dialysis. Diabetes mellitus, dyslipidemia, hypertension, inflammation and hyperhomocyteinemia are major cardiovascular risk factors. Aim: to evaluate the effects of Icodextrin and amino acid peritoneal dialysis fluid (AAPDF) on these major cardiovascular risk factors looking for a more biocompatible PDF formula. Methods: 24 adult stable peritoneal dialysis patients were included in the study. 12 patients received 2L Icodextrin and other 12 patients received 2L AAPDF in their dialysis prescription for 8 weeks. Results: Icodextrin decreased fasting plasma glucose (p Conclusions: A biocompatible PDF should provide not only adequate dialysis and ultrafiltration but should also improve nutritional and metabolic status, blood pressure control and reduce inflammation and plasma homocyteine.